A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Trial details
- Registry ID
- NCT05551117
- Phase
- Phase 2
The FDA approved Enzalutamide (Xtandi) on 31 Aug 2012.
Drug identity checked against registry records
Also recorded as Xtandi
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117 | MacroGenics | Phase 2 | Terminated | 2024-07-04Actual |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574 | Exelixis | Phase 3 | Enrolling by invitation | 2030-05-31Estimated |
| Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 | Exelixis | Phase 3 | Active not recruiting | 2024-04-19Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2012-08-31Day | Enzalutamide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA203415", "applicant_as_listed_by_fda": "ASTELLAS", "brand_names": ["XTANDI"], "active_ingredients": ["ENZALUTAMIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20120831", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |